Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Elizabeth, Schappell"'
Autor:
Kelsey M, Sumner, Ruth A, Karron, Melissa S, Stockwell, Fatimah S, Dawood, Joseph B, Stanford, Alexandra, Mellis, Emily, Hacker, Priyam, Thind, Maria Julia E, Castro, John Paul, Harris, Maria, Deloria Knoll, Elizabeth, Schappell, Marissa K, Hetrich, Jazmin, Duque, Zuha, Jeddy, Kim, Altunkaynak, Brandon, Poe, Jennifer, Meece, Elisha, Stefanski, Suxiang, Tong, Justin S, Lee, Ashton, Dixon, Vic, Veguilla, Melissa A, Rolfes, Christina A, Porucznik, Suzanne, Woods
Publikováno v:
Open forum infectious diseases. 9(8)
Background Households are common places for spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated factors associated with household transmission and acquisition of SARS-CoV-2. Methods Households with children age Res
Autor:
Jennifer Libous, Cindy Luongo, Laura Fearn, Lijuan Yang, Petronella Muresan, Elizabeth Schappell, Coleen K. Cunningham, Ruth A. Karron, Charlotte Perlowski, Elizabeth J. McFarland, Mikhaela Cielo, Patrick Jean-Philippe, Emily Barr, Jack Moye, Vivian Rexroad, Peter L. Collins, Andrew Wiznia, Jaime G. Deville, Jennifer Oliva, Ursula J. Buchholz
Publikováno v:
J Infect Dis
Background Respiratory syncytial virus (RSV) is the leading viral cause of severe pediatric respiratory illness, and vaccines are needed. Live RSV vaccine D46/NS2/N/ΔM2-2-HindIII, attenuated by deletion of the RSV RNA regulatory protein M2-2, is bas
Autor:
Bhagvanji Thumar, Devasena Gnanashanmugam, Jack Moye, Mariam Aziz, Charlotte Perlowski, Stephen A. Spector, Ruth A. Karron, Petronella Muresan, Emily Barr, Vivian Rexroad, Mikhaela Cielo, Elizabeth Schappell, Ursula J. Buchholz, Laura Fearn, Christy Beneri, Andrew Wiznia, Elizabeth J. McFarland, Jennifer Libous, Cindy Luongo, Peter Collins, Coleen K. Cunningham
Publikováno v:
J Infect Dis
Background The safety and immunogenicity of live respiratory syncytial virus (RSV) candidate vaccine, LID/ΔM2-2/1030s, with deletion of RSV ribonucleic acid synthesis regulatory protein M2-2 and genetically stabilized temperature-sensitivity mutatio
Autor:
Ruth A, Karron, Marissa K, Hetrich, Yu Bin, Na, Maria Deloria, Knoll, Elizabeth, Schappell, Jennifer, Meece, Erika, Hanson, Suxiang, Tong, Justin S, Lee, Vic, Veguilla, Fatimah S, Dawood, Samuel, Shepard
Publikováno v:
JAMA Network Open. 5:e2227348
ImportanceFew studies have prospectively assessed SARS-CoV-2 community infection in children aged 0 to 4 years. Information about SARS-CoV-2 incidence and clinical and virological features in young children could help guide prevention and mitigation
Publikováno v:
Microsystems & Nanoengineering, Vol 6, Iss 1, Pp 1-11 (2020)
In this work, we introduce a roll-to-roll system that can continuously print three-dimensional (3D) periodic nanostructures over large areas. This approach is based on Langmuir-Blodgett assembly of colloidal nanospheres, which diffract normal inciden
Autor:
Vivian Rexroad, Devasena Gnanashanmugam, Cindy Luongo, Richard M. Rutstein, Bhagvanji Thumar, Ursula J. Buchholz, Emily Barr, Jaime G. Deville, Lijuan Yang, Elizabeth J. McFarland, Mariam Aziz, Jack Moye, Petronella Muresan, Elizabeth Schappell, Ruth A. Karron, Jennifer Libous, Charlotte Perlowski, Coleen K. Cunningham, Peter Collins
Publikováno v:
Open Forum Infectious Diseases
Background The live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2 is attenuated through deletion of M2-2 and 5 cold-passage mutations. Methods RSV-seronegative children aged 6–24 months received a single intranasal dose of 105 pla
Autor:
Megan Valentine, Emily Barr, Petronella Muresan, Cindy Luongo, Ruth A. Karron, Coleen K. Cunningham, Peter L. Collins, Vivian Rexroad, Devasena Gnanashanmugam, Elizabeth Schappell, Ursula J. Buchholz, Ram Yogev, George K. Siberry, Bhagvinji Thumar, Stephen A. Spector, Mariam Aziz, Charlotte Perlowski, Paul A. Sato, Elizabeth J. McFarland
Publikováno v:
The Journal of infectious diseases. 217(9)
BACKGROUND: Respiratory syncytial virus (RSV) is the most important viral cause of severe respiratory illness in young children and lacks a vaccine. RSV cold-passage/stabilized 2 (RSVcps2) is a modification of a previously evaluated vaccine candidate
Autor:
Stephen A. Spector, Ruth A. Karron, Bhagvanji Thumar, Megan Valentine, Elizabeth Schappell, Mikhaela Cielo, Coleen K. Cunningham, Ursula J. Buchholz, Petronella Muresan, Charlotte Perlowski, Mariam Aziz, Devasena Gnanashanmugam, George K. Siberry, Nehali Patel, Peter L. Collins, Ram Yogev, Emily Barr, Vivian Rexroad, Elizabeth J. McFarland, Cindy Luongo
Publikováno v:
The Journal of infectious diseases. 217(9)
BACKGROUND: Live respiratory syncytial virus (RSV) candidate vaccine LIDΔM2-2 is attenuated by deletion of the RSV RNA regulatory protein M2-2, resulting in upregulated viral gene transcription and antigen expression but reduced RNA replication. MET
Autor:
Janet A, Englund, Ruth A, Karron, Coleen K, Cunningham, Philip, Larussa, Ann, Melvin, Ram, Yogev, Ed, Handelsman, George K, Siberry, Bhavanji, Thumar, Elizabeth, Schappell, Catherine V, Bull, Helen Y, Chu, Anne, Schaap-Nutt, Ursula, Buchholz, Peter L, Collins, Alexander C, Schmidt, Catherine, Bull
Publikováno v:
Vaccine
Human parainfluenza virus type 3 (HPIV3) is a common cause of upper and lower respiratory tract illness in infants and young children. Live-attenuated cold-adapted HPIV3 vaccines have been evaluated in infants but a suitable interval for administrati
Autor:
Sonja R. Surman, Bhagvanji Thumar, Alexander C. Schmidt, Peter L. Collins, Elizabeth Schappell, Ruth A. Karron, Brian R. Murphy
Publikováno v:
Vaccine
Human parainfluenza virus type 3 (HPIV3) is an important cause of lower respiratory tract illness in children, yet a licensed vaccine or antiviral drug is not available. We evaluated the safety, tolerability, infectivity, and immunogenicity of two in